相关实验视频
Updated: Jul 18, 2025

08:36
Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
Published on: April 7, 2023
1.1K
多发性关节炎中托法西替尼的长期保留率:意大利多中心回顾性队列研究
Marino Paroli1, Andrea Becciolini2, Elena Bravi3
1Department of Clinical, Internist, Anesthesiologic and Cardiovascular Sciences, Sapienza University of Rome, 00185 Rome, Italy.
Medicina (Kaunas, Lithuania)
|August 26, 2023
概括
在现实临床实践中,托法西替尼 (TOFA) 在风湿性关节炎 (RA) 患者的48个月内显示出良好的保留率. 这种 Janus 激酶抑制剂 (JAKi) 是 RA 患者的可行治疗选择,这些患者对其他疗法没有反应.
科学领域:
- 类风湿病学 类风湿病学
- 药理学 药理学是指药理学的学科.
- 临床医学 临床医学
背景情况:
- 托法西替尼 (TOFA) 是第一个被批准用于类风湿性关节炎 (RA) 的Janus激酶抑制剂 (JAKi).
- 在现实环境中,关于TOFA治疗保留率的最终数据仍然有限.
- 这项研究旨在提供新的真实数据,以长期保留TOFA.
研究的目的:
- 评估托法西提尼布 (TOFA) 在类风湿性关节炎 (RA) 患者队列中的长期保留率.
- 在现实临床环境中评估影响TOFA停药的因素.
主要方法:
- 一项多中心的回顾性研究,涉及来自23个意大利风湿病中心的213名RA患者.
- 患者接受了TOFA单一治疗或与常规合成疾病修饰性抗风湿药物 (csDMARDs) 结合治疗.
- 卡普兰-梅尔法评估了TOFA保留率高达48个月; 考克斯回归分析了戒断预测因素.
主要成果:
- 在12个月后,TOFA的保留率为86.5%,在24个月后为78.8%,在36个月后为63.8%,在48个月后为59.9%.
- 没有分析的因素 (先前的治疗,疾病活动,人口统计,并发症) 预测TOFA保留.
- 安全数据与注册研究的结果一致.
结论:
- 在现实实践中,托法西提尼 (TOFA) 在类风湿性关节炎 (RA) 患者中显示出有利的长期保留率.
- 托法是一种可行的治疗替代方案,用于那些失败了csDMARDs和/或生物DMARDs (bDMARDs) 的RA患者.
- 需要进一步的大规模,长期的观察性研究来验证这些发现.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
173
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
173
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
150
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
150
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
195
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
195
Pharmacovigilance
889
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
889
Clinical Trials: Overview
3.0K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.0K
Drugs for Treatment of Ulcerative Colitis in IBD
173
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
173

